Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Jul 2024. Module: IPS terminology module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3678502014 | Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| 3678504010 | Product containing precisely efavirenz 600 milligram and emtricitabine 200 milligram and tenofovir disoproxil fumarate 300 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Is a | Medicinal product (product) | true | Inferred relationship | Some | ||
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has basis of strength substance (attribute) | Tenofovir disoproxil fumarate (substance) | true | Inferred relationship | Some | 1 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has precise active ingredient | Tenofovir disoproxil fumarate (substance) | true | Inferred relationship | Some | 1 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has basis of strength substance (attribute) | Efavirenz (substance) | true | Inferred relationship | Some | 2 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has precise active ingredient | Efavirenz (substance) | true | Inferred relationship | Some | 2 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has basis of strength substance (attribute) | Emtricitabine (substance) | true | Inferred relationship | Some | 3 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 3 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 3 | |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet | Has precise active ingredient | Emtricitabine (substance) | true | Inferred relationship | Some | 3 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
FHIR